Differentiation therapy has been shown to have a significant clinical antitumour activity in acute promyelocytic leukemia, and promising preclinical activity in liposarcoma and osteosarcoma [45, 46], this outlining the importance to test the antitumour effects of this EPH inhibitor in xenograft models [21]. This evidence concerns the gene EPHA1 and acute promyelocytic leukemia.